Influenza nanoparticle vaccine trivalent - Novavax
Alternative Names: Novavax flu vaccine; tNIV 1; tNIV 1 - NovavaxLatest Information Update: 29 Jul 2024
At a glance
- Originator Novavax
- Class Influenza virus vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Influenza virus infections
Most Recent Events
- 18 Jul 2024 Clinical trials in Influenza virus infections (Prevention) (IM)
- 18 Jul 2024 Novavax plans a phase II/III trial in Influenza virus infections (Prevention, In adults, In the elderly) [IM,Injection] in December 2024 (NCT06485752)